ELAN vs COR vs IDXX Stock Comparison

Elanco Animal Health, Cencora and Idexx Laboratories Prices as of Nov 13, 2026 Peers: Industry group
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
5 wins

Head to Head

11 decided of 12

Cencora leads on 5 of the 12 questions below (Cencora 5, Idexx Laboratories 4, Elanco Animal Health 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANCORIDXXLeader
Larger companyMarket capitalisation $13.25B $69.10B $55.34B COR
Cheaper on earningsLower P/E, profitable companies only -90.2x 22.6x 46.8x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.7x 18.8x 44.6x COR
Faster revenue growthRevenue growth, trailing twelve months +12.1% +5.0% +11.9% ELAN
More profitableNet margin, trailing twelve months -2.9% — 25.4% IDXX
Better return on capitalReturn on invested capital 6.9% — 45.4% IDXX
Less leveragedLower net debt / EBITDA 2.3x — 0.4x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +21.8% -1.8% +0.4% ELAN
Better 5-year returnAnnualised price return, 5 years -4.1%/yr +23.4%/yr +2.3%/yr COR
Less volatileAnnualised volatility, 1 year 43.4% 33.4% 36.2% COR
Higher overall scoreMean of the five percentile scores vs peers 69/100 56/100 76/100 IDXX

Percentile Scorecard

ELANCORIDXX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANCORIDXX
Valuation 92 #52 of 660 54 #13 of 27 74 #175 of 660
Growth 67 #208 of 619 64 #10 of 26 70 #184 of 619
Profitability 85 #90 of 595 64 #10 of 26 98 #12 of 595
Financial Health 31 #473 of 683 – 46 #371 of 683
Shareholder Returns 73 #126 of 459 41 #11 of 18 94 #30 of 459
Overall 69 56 76
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANCORIDXXSPY
1 month +18.8%+6.8%+33.1% -2.0%
3 months +13.2%+14.4%+27.8% -2.8%
6 months +34.9%+39.3%+33.2% +2.0%
Year to date +18.4%+6.3%+4.1% +10.6%
1 year +21.8%-1.8%+0.4% +12.2%
3 years +136.2%+84.7%+55.0% +68.1%
3 years, per year +33.2%+22.7%+15.7% +18.9%
5 years -18.9%+186.4%+12.1% +61.4%
5 years, per year -4.1%+23.4%+2.3% +10.1%
10 years —+354.9%+545.1% +248.5%
10 years, per year —+16.4%+20.5% +13.3%

Risk

MeasureELANCORIDXXSPY
Volatility, 1Y 43.4%33.4%36.2% 13.6%
Downside volatility, 1Y 43.7%40.0%32.6% 13.9%
Beta vs S&P 500, 1Y 1.320.050.84 1.00
Return / volatility, 1Y 0.50-0.050.01 0.90
Max drawdown, 5Y -75.0%-32.6%-50.9% -25.4%
From 52-week high -0.2%-4.2%-8.1% -3.2%
52-week high $26.84$374.75$766.68 $779.14
52-week low $19.80$252.74$504.70 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANCORIDXX
P/E now vs peer median -91.1xmedian 17.0x 22.6xmedian 25.2x 47.0xmedian 17.0x
P/S now vs peer median 2.6xmedian 8.4x 0.2xmedian 0.4x 11.9xmedian 8.4x
EV/EBITDA now vs peer median 11.8xmedian 14.6x —median 14.5x 33.7xmedian 14.6x
P/FCF now vs peer median 32.8xmedian 19.0x 14.5xmedian 16.5x 42.6xmedian 19.0x
P/B now vs peer median 2.0xmedian 2.0x 18.6xmedian 2.7x 29.7xmedian 2.0x
PEG now vs peer median -1.82median 0.43 —median 1.72 3.10median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANCORIDXX
Revenue $5.15B $337.40B $4.66B
Gross profit $2.89B $13.87B $2.92B
Operating income $720.00M $3.93B $1.51B
Net income -$147.00M $3.51B $1.18B
Free cash flow $408.00M – $1.30B
R&D $381.00M – $266.87M
EPS (diluted) $-0.29 – $14.96
Cash & equivalents $465.00M $4.88B $197.54M
Total debt $3.71B – $848.88M
Shares (diluted) 506.50M 193.94M 79.05M
Enterprise value $11.29B $69.10B $54.56B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANCORIDXX
P/E -91.1x 22.6x 47.0x
P/FCF 32.8x 14.5x 42.6x
P/Operating cash flow 21.8x 14.3x 39.1x
P/S 2.6x 0.2x 11.9x
P/B 2.0x 18.6x 29.7x
P/Tangible book 3.7x 18.6x 31.7x
EV/EBITDA 11.8x – 33.7x
EV/EBIT 23.1x – 37.3x
EV/Revenue 3.2x 0.2x 12.0x
EV/FCF 40.8x – 43.1x
EV/Operating cash flow 27.1x 14.3x 39.6x
PEG (3Y EPS CAGR) -1.82 – 3.10

Growth

14 metrics
MetricELANCORIDXX
Revenue growth (1Y) 12.1% 5.0% 11.9%
Revenue CAGR (3Y) 5.6% 8.8% 9.1%
Gross profit growth (1Y) 14.6% 20.8% 13.7%
Gross profit CAGR (3Y) 4.9% 15.7% 10.8%
Operating income growth (1Y) 20.6% 49.5% 15.3%
Operating income CAGR (3Y) 41.2% 18.9% 11.8%
Net income growth (1Y) -508.3% 124.0% 15.1%
Net income CAGR (3Y) 49.5% 26.3% 12.8%
EPS growth (1Y) -500.5% – 17.4%
EPS CAGR (3Y) 50.0% – 15.1%
Operating cash flow growth (1Y) -2.4% 23.6% 30.4%
Operating cash flow CAGR (3Y) 69.1% 7.0% 19.6%
Free cash flow growth (1Y) 10.9% – 35.3%
Free cash flow CAGR (3Y) 117.8% – 24.2%

Profitability

14 metrics
MetricELANCORIDXX
Gross margin 56.2% – 62.7%
EBITDA margin 27.5% – 35.7%
Operating margin 14.0% – 32.3%
Pretax margin -1.8% – 31.7%
Net margin -2.9% – 25.4%
FCF margin 7.9% – 28.0%
Operating cash flow margin 11.9% 1.4% 30.4%
Return on equity -2.2% 101.2% 67.9%
Return on assets -1.1% 4.1% 33.1%
Return on invested capital 6.9% – 45.4%
Return on capital employed 6.2% – 65.2%
Asset turnover 0.4x 3.9x 1.3x
Cash conversion (OCF / net income) -4.2x 1.4x 1.2x
Stock comp / revenue 1.5% – 1.4%

Financial Health

11 metrics
MetricELANCORIDXX
Debt / assets 27.8% – 22.9%
Debt / equity 0.6x – 0.5x
Net debt / EBITDA 2.3x – 0.4x
Debt / FCF 9.1x – 0.7x
Liabilities / assets 50.3% – 49.6%
Equity / assets 49.7% 4.2% 50.4%
Interest coverage 2.8x – 43.5x
Current ratio 2.1x 0.9x 1.2x
Quick ratio 0.9x – 0.7x
Cash ratio 0.3x – 0.2x
Altman Z-score 1.72 – 23.56

Shareholder Returns

7 metrics
MetricELANCORIDXX
Dividend yield – 0.9% –
Net buyback yield -0.3% – 1.7%
Shareholder yield -0.3% 0.9% 1.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANCORIDXX
Forward P/E 23.7xFY2026 18.8xFY2027 44.6xFY2026
EPS, next fiscal year $1.13FY2026 $19.07FY2027 $15.78FY2026
EPS growth, next FY +20.2%FY2026 +6.1%FY2027 +20.6%FY2026
EPS growth, the year after +22.1% +17.4% +12.3%
Revenue, next fiscal year $4.82BFY2026 $328.27BFY2027 $5.03BFY2026
Revenue growth, next FY +2.4%FY2026 -2.7%FY2027 +17.0%FY2026
Revenue growth, the year after +19.4% +19.1% +0.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANCORIDXX
Held by institutions 100.0% 94.7% 93.6%
Institutions holding 526 1,345 1,292
Change in shares held, QoQ +4.4% +15.7% +4.1%
Institutions buying 246 542 590
Institutions selling 211 612 496
Buyers to sellers 1.17 0.89 1.19

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANCORIDXX
ELAN 1.00 -0.03 0.42
COR -0.03 1.00 0.17
IDXX 0.42 0.17 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ELAN, COR and IDXX?

Cencora (COR) is the largest by market capitalisation: Elanco Animal Health (ELAN) $13.25B, Cencora (COR) $69.10B, Idexx Laboratories (IDXX) $55.34B.

Which stock is cheaper, ELAN, COR and IDXX?

Cencora (COR) trades on the lowest price-to-earnings ratio (Elanco Animal Health (ELAN) -90.2x, Cencora (COR) 22.6x, Idexx Laboratories (IDXX) 46.8x). On next year's consensus earnings, Cencora (COR) is cheapest (Elanco Animal Health (ELAN) 23.7x, Cencora (COR) 18.8x, Idexx Laboratories (IDXX) 44.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Elanco Animal Health (ELAN) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.1%, Cencora (COR) +5.0%, Idexx Laboratories (IDXX) +11.9%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Idexx Laboratories (IDXX) 25.4%). On return on invested capital, Idexx Laboratories (IDXX) leads (Elanco Animal Health (ELAN) 6.9%, Idexx Laboratories (IDXX) 45.4%).

Which stock has performed better?

Over the past year Elanco Animal Health (ELAN) returned the most: Elanco Animal Health (ELAN) +21.8%, Cencora (COR) -1.8%, Idexx Laboratories (IDXX) +0.4%. Over five years, Cencora (COR) compounded fastest (Elanco Animal Health (ELAN) -4.1%/yr, Cencora (COR) +23.4%/yr, Idexx Laboratories (IDXX) +2.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Elanco Animal Health (ELAN) 43.4%, Cencora (COR) 33.4%, Idexx Laboratories (IDXX) 36.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, COR and IDXX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cencora (COR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.